Dario expands glp-1 solution client base with new employer contract

Dario's leading behavior change solutions continue to win interest in the employer, payer and pharmaceutical markets new york , july 16, 2024 /prnewswire/ -- dariohealth corp. (nasdaq: drio) ("dario" or the "company"), a leader in the global digital health market, announced today a new contract with a national employer to provide its cardiometabolic solution with integrated support for glp-1s to employees beginning in the third quarter of 2024. the employer, a leader in environmental services, selected dario's cardiometabolic suite to address multiple health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including integrated support for those employees taking a glp-1 medication.
DRIO Ratings Summary
DRIO Quant Ranking